Who gets to advise the FDA on multiple sclerosis drugs and treatments?
There have been several new MS drugs brought to market in the five years since CCSVI research was first discussed in medical journals. We have to wonder whether the process of hastening these new drugs to market was aided by the influence of phamaceutical companies.
In the news today, e-mails are released that show pharmaceutical companies pay to attend FDA advisory meetings and submit their own recommendations on drugs to be marketed, http://www.washingtonpost.com/business/economy/pharmaceutical-firms-paid-to-attend-meetings-of-panel-that-advises-fda-e-mails-show/2013/10/06/a02a2548-2b80-11e3-b139-029811dbb57f_story.html?hpid=z1
I thought it might be a good idea to see what information is available to the public regarding who is recommending MS treatments to the FDA, and how they do this.
The group that looks at evidence for the MS community and advises on drug approval is the
"Peripheral and Central Nervous System Drugs Advisory Committee"
There are many reports prepared by pharmaceutical companies to be submitted to this group, which are available for public disclosure without redaction on the FDA.gov site.
Here is one for Fingolimod, now marketed as Gilenya-- prepared by Novartis- and submitted to the advisory committee for their June 10th, 2010 meeting.
The authors are free-lance biotechnicians who specialize in "bringing pharmaceuticals to market."
The FDA advisory committee decided that day to approve Fingolimod/Gilenya and made the announcement to the press. They were giddy with the fact that this drug was the first FDA approved oral medication for people with MS.
What is important to note is that by the time 2012 came around, the FDA had to issue a formal warning on Gilenya, due to several deaths and cardiac events reported after the drug was marketed to pwMS. These cardiac deaths and side-effects were not flagged by the FDA, or Novartis---but reported by a non profit watchdog group, the Institute for Safe Medication Practices.
Recently, the Institute for Safe Medication Practices, a nonprofit watchdog group, has urged the FDA to put more restrictions on the use of Gilenya. The group reviewed the number of side effects of the drug reported to the FDA MedWatch program in the second quarter of 2011, and it concluded that "the FDA and manufacturer should consider substantial restrictions on its use and enhanced monitoring."
Here is the strongly worded comment from the ISMP--
It was a significant gamble for the FDA to allow unrestricted marketing of powerful but novel immunosuppressant drug before determining the optimal dose and learning more about its long term risks. Only about 300 people were exposed to fingolimod for a period of two years prior to approval.
